Company news
Phio Pharmaceuticals Corp. news in 2023
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2023, newest first.
Phio Pharmaceuticals Announces Exercise of Warrants for $2.8 Million Gross Proceeds
December 6, 2023
Phio Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Update
November 8, 2023
Phio Pharmaceuticals Announces First US Patient Enrolled in Phase 1B Clinical Trial with Intratumoral PH-762 anti-PD-1 Therapy for Treatment of Skin Carcinomas
November 8, 2023
Phio Pharmaceuticals Presents New Data Showing INTASYL Compound targeting CTLA-4 Enhances Tumor Control
November 2, 2023
Phio Pharmaceuticals Announces Upcoming Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 11, 2023
Phio Pharmaceuticals Presents New Data for Targeting of BRD4 with its INTASYL™ Compound PH-894
October 10, 2023
Phio Pharmaceuticals Announces Dosing of First Patient in Collaborative Clinical Trial with AgonOx, Inc. and Providence Cancer Institute
August 20, 2023
Phio Pharmaceuticals Announces $4 Million Concurrent Registered Direct Offering and Private Placement Priced At-the-Market Under Nasdaq Rules
May 30, 2023
Phio Pharmaceuticals Announces Initiation of Collaborative Clinical Trial with PH-762, AgonOx's Tumor Infiltrating Lymphocyte Program (AGX148) and Providence Cancer Institute
May 23, 2023
Phio Pharmaceuticals Presents Preclinical Study Showing INTASYL™ Treatment of NK Cells More than Doubles Ability to Kill Tumor Cells
May 17, 2023
Phio Pharmaceuticals Announces FDA Clearance to Initiate Clinical Trial of PH-762 for Treatment of Skin Carcinomas
May 15, 2023
Phio Pharmaceuticals Reports First Quarter 2023 Financial Results and Provides Business Update
May 10, 2023
Phio Pharmaceuticals Presents Preclinical Data Demonstrating Synergy-Enhanced in vivo Anti-Tumor Efficacy of PD-1/CTLA-4 Dual-Targeting INTASYL
April 17, 2023
Phio Pharmaceuticals Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
April 17, 2023
Phio Pharmaceuticals Presents Preclinical Study Showing PH-762 Induces Systemic Memory T Cell Mediators of Anti-Tumor Immunity
April 16, 2023
Phio Pharmaceuticals Reports 2022 Year End Financial Results and Provides Business Update
March 21, 2023
Phio Pharmaceuticals Appoints Robert Bitterman as President and Chief Executive Officer
February 21, 2023
Phio Pharmaceuticals Regains Compliance with Nasdaq Listing Requirements
February 12, 2023
Phio Pharmaceuticals Announces Positive DMC Recommendation and Continued Enrollment of Advanced Melanoma Study Without Modification
February 9, 2023
Phio Pharmaceuticals Announces Regulatory Clearance of Clinical Trial With PH-762 and AgonOx's Tumor Infiltrating Lymphocytes (AGX148) to Treat Solid Tumors
January 5, 2023
Decks in 2023
- Investor Presentation (January 2023)
Investor deck · 18 slides · Jan 6, 2023